CSIMarket Company Name, Ticker, Customers, else..
 
Neurosense Therapeutics Ltd  (NASDAQ: NRSN)
 

Neurosense Therapeutics Ltd's Suppliers Performance

NRSN's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
NRSN Costs vs Sales of Suppliers Growth

• More on NRSN Suppliers






Neurosense Therapeutics Ltd's Comment on Supply Chain


The company depends on third-party contract manufacturers and suppliers for all raw materials, active ingredients, and finished products required for preclinical studies, clinical trials, and potential commercial production of PrimeC. This reliance presents risks related to limited suppliers, potential challenges in meeting increased demand, lack of control over raw material availability, and dependence on third parties for regulatory compliance and quality assurance. Disruptions or noncompliance by these suppliers could delay product development or commercialization and may lead to regulatory sanctions. The company intends to maintain this reliance on third-party providers if PrimeC or other product candidates receive regulatory approval.

Neurosense Therapeutics Ltd's Comment on Supply Chain


The company depends on third-party contract manufacturers and suppliers for all raw materials, active ingredients, and finished products required for preclinical studies, clinical trials, and potential commercial production of PrimeC. This reliance presents risks related to limited suppliers, potential challenges in meeting increased demand, lack of control over raw material availability, and dependence on third parties for regulatory compliance and quality assurance. Disruptions or noncompliance by these suppliers could delay product development or commercialization and may lead to regulatory sanctions. The company intends to maintain this reliance on third-party providers if PrimeC or other product candidates receive regulatory approval.







NRSN's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Neurosense Therapeutics Ltd 8.85 0.00 -11.13 16
SUBTOTAL 0.00 0.00 0.00 -


Sources: Neurosense Therapeutics Ltd's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Neurosense Therapeutics Ltd’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.